Bent Jakobsen

Bent Jakobsen is a prominent figure in the biotechnology sector, currently serving as the Chairman of the Board at Engimmune Therapeutics, a position he has held since May 2022. Engimmune focuses on developing novel T-cell receptor (TCR) therapeutics, leveraging AI-guided innovation and laboratory insights to advance its pipeline of soluble TCR engagers.24

Professional Background

• Founder and CEO of Accession Therapeutics Limited since June 2021, where he is involved in the development of innovative cancer therapies.1
• Co-Founder and Board Member of SynaptixBio Ltd., also established in May 2021, focusing on biotherapeutics.1
• Previously, he was a Chief Scientific Officer and co-founder of Adaptimmune Therapeutics PLC, where he contributed significantly to the development of T-cell therapies from 2008 to 2015.13

Notable Achievements

Jakobsen co-founded Immunocore Ltd in 2008, a company that specializes in soluble TCR therapeutics. Under his leadership, Immunocore entered into strategic partnerships with major pharmaceutical companies such as Genentech and GlaxoSmithKline, advancing its clinical programs.15 His expertise in T-cell receptor technology has made him a recognized leader in the field of immunotherapy.

Current Roles

In addition to his role at Engimmune, Bent Jakobsen serves on the boards of several other companies, including:

• Zelluna Immunotherapy AS as a Board Member and Advisor.
• Nextera AS as a Board Member.
• Etcembly Ltd, also as a Board Member.15

Jakobsen's extensive experience and leadership in the biotechnology industry position him as a key player in advancing cancer therapeutics through innovative approaches.